Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis-A systematic review and meta-analysis

被引:30
作者
Theurich, Sebastian [1 ]
Fischmann, Hans [1 ]
Chakupurakal, Geothy [1 ]
Shimabukuro-Vomhagen, Alexander [1 ]
Chemnitz, Jens M. [1 ]
Holtick, Udo [1 ]
Rothe, Achim [1 ]
Scheid, Christof [1 ]
Hallek, Michael [1 ]
Skoetz, Nicole [2 ]
von Bergwelt-Baildon, Michael [1 ]
机构
[1] Univ Hosp Cologne, Stem Cell Transplantat Program, Dept Internal Med 1, D-50937 Cologne, Germany
[2] Univ Hosp Cologne, Cochrane Haematol Malignancies Grp, Dept Internal Med 1, D-50937 Cologne, Germany
关键词
Allogeneic stem cell transplantation; Bone marrow transplantation; Graft-versus-host disease; GvHD; Anti-thymocyte globulins; ATG; Systematic review; Meta-analysis; HEMATOPOIETIC-CELL TRANSPLANTATION; ANTITHYMOCYTE GLOBULIN; RANDOMIZED-TRIAL; UNRELATED DONORS; MARROW-TRANSPLANTATION; APLASTIC-ANEMIA; RECIPIENTS; PHASE-3;
D O I
10.1016/j.critrevonc.2013.03.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Despite advances made in allogeneic hematopoietic stem cell transplantation (alloSCT), graft versus host disease (GvHD) remains a major problem. The main strategy to combat GvHD is prophylaxis and ATG plays a major role in this arena. Conflicting reports on the effectiveness of ATG on GvHD prevention prompted us to address this question by means of a systematic review and meta-analysis. Methods: Six prospective randomized controlled trials (RCT) comparing the addition of ATG to standard immunosuppressive regimen as GvHD prophylaxis were analyzed. All ATG preparations were considered but homogeneity in type of preparation and dosage had to be observed within each trial. Results: Our meta-analysis reveals that the incidence of grade II-IV GvHD was significantly lower in patients receiving ATG. Addition of ATG had no impact on overall survival, relapse or non-relapse mortality. Conclusions: Based on the current level of the data analyzed in this systematic review, we cannot conclude a general recommendation for the use of ATG for GvHD prophylaxis in alloSCT. In patients who are at high risk for severe GvHD it should be considered individually. However, due to the heterogeneity of the analyzable studies it seems likely that future studies might change the results of the pooled data of this meta-analysis. In order to improve the current level of data, further randomized studies in this topic are therefore urgently warranted. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:178 / 186
页数:9
相关论文
共 20 条
[1]   Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects [J].
Bacigalupo, A .
BONE MARROW TRANSPLANTATION, 2005, 35 (03) :225-231
[2]   Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: Long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation [J].
Bacigalupo, A ;
Lamparelli, T ;
Barisione, G ;
Bruzzi, P ;
Guidi, S ;
Alessandrino, PE ;
di Bartolomeo, P ;
Oneto, R ;
Bruno, B ;
Sacchi, N ;
van Lint, MT ;
Bosi, A .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (05) :560-565
[3]   Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants [J].
Bacigalupo, A ;
Lamparelli, T ;
Gualandi, F ;
Bregante, S ;
Raiola, AM ;
Di Grazia, C ;
Dominietto, A ;
Bruno, B ;
Galbusera, V ;
Frassoni, F ;
Podesta, M ;
Tedone, E ;
Occhini, D ;
Van Lint, MT .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (12) :656-661
[4]   Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO) [J].
Bacigalupo, A ;
Lamparelli, T ;
Bruzzi, P ;
Guidi, S ;
Alessandrino, PE ;
di Bartolomeo, P ;
Oneto, R ;
Bruno, B ;
Barbanti, M ;
Sacchi, N ;
Van Lint, MT ;
Bosi, A .
BLOOD, 2001, 98 (10) :2942-2947
[5]   Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens [J].
Champlin, Richard E. ;
Perez, Waleska S. ;
Passweg, Jakob R. ;
Klein, John P. ;
Camitta, Bruce M. ;
Gluckman, Eliane ;
Bredeson, Christopher N. ;
Eapen, Mary ;
Horowitz, Mary M. .
BLOOD, 2007, 109 (10) :4582-4585
[6]   FAILURE OF EARLY ADMINISTRATION OF ANTI-THYMOCYTE GLOBULIN TO LESSEN GRAFT VERSUS HOST-DISEASE IN HUMAN ALLOGENEIC MARROW TRANSPLANT RECIPIENTS [J].
DONEY, KC ;
WEIDEN, PL ;
STORB, R ;
THOMAS, ED .
TRANSPLANTATION, 1981, 31 (02) :141-143
[7]   Graft-versus-host disease [J].
Ferrara, James L. M. ;
Levine, John E. ;
Reddy, Pavan ;
Holler, Ernst .
LANCET, 2009, 373 (9674) :1550-1561
[8]   Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial [J].
Finke, Juergen ;
Bethge, Wolfgang A. ;
Schmoor, Claudia ;
Ottinger, Hellmut D. ;
Stelljes, Matthias ;
Zander, Axel R. ;
Volin, Liisa ;
Ruutu, Tapani ;
Heim, Dominik A. ;
Schwerdtfeger, Rainer ;
Kolbe, Karin ;
Mayer, Jiri ;
Maertens, Johan A. ;
Linkesch, Werner ;
Holler, Ernst ;
Koza, Vladimir ;
Bornhaeuser, Martin ;
Einsele, Hermann ;
Kolb, Hans-Jochem ;
Bertz, Hartmut ;
Egger, Matthias ;
Grishina, Olga ;
Socie, Gerard .
LANCET ONCOLOGY, 2009, 10 (09) :855-864
[9]   Rabbit Anti T-Lymphocyte Globulin Induces Apoptosis in Peripheral Blood Mononuclear Cell Compartments and Leukemia Cells, While Hematopoetic Stem Cells Are Apoptosis Resistant [J].
Gruellich, Carsten ;
Ziegler, Christian ;
Finke, Juergen .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) :173-182
[10]   Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review [J].
Kumar, A. ;
Mhaskar, A. R. ;
Reljic, T. ;
Mhaskar, R. S. ;
Kharfan-Dabaja, M. A. ;
Anasetti, C. ;
Mohty, M. ;
Djulbegovic, B. .
LEUKEMIA, 2012, 26 (04) :582-588